Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis
- PMID: 15529257
- DOI: 10.1086/425516
Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis
Abstract
Respiratory syncytial virus (RSV) is an important cause of severe lower respiratory tract illness in infants and the elderly. Presently, no safe and efficacious RSV vaccine exists; however, advances in our understanding of immunity and the pathogenesis of disease associated with RSV infection may lead to new vaccine strategies. RSV G protein contains a CX3C chemokine motif that interacts with the CX3CR1 chemokine receptor and modifies the activities of fractalkine. In the present study, we show that anti-RSV G protein antibody responses after recent RSV infection or vaccination are associated with inhibition of RSV G protein CX3C-CX3CR1 interaction and RSV G protein-mediated leukocyte chemotaxis.
Similar articles
-
Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies.Viruses. 2021 Feb 23;13(2):352. doi: 10.3390/v13020352. Viruses. 2021. PMID: 33672319 Free PMC article.
-
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.J Virol. 2010 Jan;84(2):1148-57. doi: 10.1128/JVI.01755-09. Epub 2009 Oct 28. J Virol. 2010. PMID: 19864390 Free PMC article.
-
Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.J Virol. 2017 Apr 28;91(10):e02059-16. doi: 10.1128/JVI.02059-16. Print 2017 May 15. J Virol. 2017. PMID: 28275196 Free PMC article.
-
Immunopathology of RSV infection: prospects for developing vaccines without this complication.Rev Med Virol. 2007 Jan-Feb;17(1):5-34. doi: 10.1002/rmv.518. Rev Med Virol. 2007. PMID: 17004293 Review.
-
Clinical experience with respiratory syncytial virus vaccines.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S94-9. doi: 10.1097/01.inf.0000053893.15894.ff. Pediatr Infect Dis J. 2003. PMID: 12671459 Review.
Cited by
-
Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15).Virol J. 2008 Oct 13;5:116. doi: 10.1186/1743-422X-5-116. Virol J. 2008. PMID: 18851747 Free PMC article.
-
Modulation of host adaptive immunity by hRSV proteins.Virulence. 2014;5(7):740-51. doi: 10.4161/viru.32225. Virulence. 2014. PMID: 25513775 Free PMC article. Review.
-
The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines.PLoS Pathog. 2021 Apr 8;17(4):e1009469. doi: 10.1371/journal.ppat.1009469. eCollection 2021 Apr. PLoS Pathog. 2021. PMID: 33831114 Free PMC article.
-
Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies.Viruses. 2021 Feb 23;13(2):352. doi: 10.3390/v13020352. Viruses. 2021. PMID: 33672319 Free PMC article.
-
Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.Virus Genes. 2006 Oct;33(2):235-52. doi: 10.1007/s11262-006-0064-x. Virus Genes. 2006. PMID: 16972040 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous